> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-199/
- Published: 2018-10-14T12:00:00.000Z
- Updated: 2026-09-15T00:38:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142586

[**Notice on Pathogen Reduction Workshop Corrected**](https://www.fdaweb.com/notice-on-pathogen-reduction-workshop-corrected/)  
*Federal Register* notice: FDA corrects a 9/17 notice announcing an 11/29 public workshop entitled “Pathogen Reduction Technologies for Blood Safety.” 10/12/2018

[**FDA Renews Dermatologic/Ophthalmic Drugs Panel Charter**](https://www.fdaweb.com/fda-renews-dermatologic-ophthalmic-drugs-panel-charter/)  
*Federal Register* notice: FDA renews the charter of its Dermatologic and Ophthalmic Drugs Advisory Committee for an additional two years. 10/11/2018

[**FDA Renews Charter for Antimicrobial Drugs Panel**](https://www.fdaweb.com/fda-renews-charter-for-antimicrobial-drugs-panel/)  
*Federal Register* notice: FDA renews for two years the charter of its Antimicrobial Drugs Advisory Committee. 10/11/2018

[**Draft Guide on Transdermal Irritation Studies**](https://www.fdaweb.com/draft-guide-on-transdermal-irritation-studies/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs.” 10/10/2018

[**List of Information Collections Approved by OMB**](https://www.fdaweb.com/list-of-information-collections-approved-by-omb-2/)  
*Federal Register* notice: FDA publishes a list of information collections that have been recently approved by OMB. 10/10/2018

[**Draft Guide on Drug Patch Adhesion Studies**](https://www.fdaweb.com/draft-guide-on-drug-patch-adhesion-studies/)  
*Federal Register* notice: FDA makes available a revised draft guidance entitled “Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs.” 10/10/2018

[**Comments Sought on WHO Drug Scheduling for 16 Drugs**](https://www.fdaweb.com/comments-sought-on-who-drug-scheduling-for-16-drugs/)  
*Federal Register* notice: FDA requests comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for 16 drug substances. 10/09/2018

[**25 New and Revised ANDA Bioequivalence Draft Guides**](https://www.fdaweb.com/25-new-and-revised-anda-bioequivalence-draft-guides/)  
*Federal Register* notice: FDA makes available two new product-specific draft guidances for submitting ANDAs for capsaicin and estradiol (norethindrone acetate), in addition to 23 other revised guidances. 10/09/2018

[**Panel to Discuss Opioid Analgesic Sparing Outcomes**](https://www.fdaweb.com/panel-to-discuss-opioid-analgesic-sparing-outcomes/)  
*Federal Register* notice: FDA announces an 11/15 Anesthetic and Analgesic Drug Products Advisory Committee meeting to discuss the assessment of opioid analgesic sparing outcomes in acute pain clinical trials. 10/08/2018